Early-Stage vs Advanced CKD Treatment

Author(s):

Rajiv Agarwal, MD,Mark A. Meeker, DO, FACP, CPE

Key Takeaways

Early-stage CKD management emphasizes lifestyle changes, blood pressure, and glycemic control to slow disease progression.
Advanced CKD treatment involves intensive interventions like dialysis or transplantation, tailored to individual patient needs.
Nonsteroidal MRAs, such as finerenone, block mineralocorticoid receptors, reducing kidney inflammation and fibrosis.
Finerenone offers potential advantages over traditional treatments, improving cardiovascular and renal outcomes in diabetic kidney disease.

Panelists discuss the treatment options available for patients with early-stage versus advanced chronic kidney disease (CKD) and how these options should be tailored to individual patient conditions, as well as the mechanism of action of nonsteroidal mineralocorticoid receptor antagonists (MRAs) such as finerenone and their comparison to other treatment modalities.

What treatment options are available for patients in early-stage versus advanced CKD, and how should they be tailored to the patient's condition
What is the mechanism of action of nonsteroidal MRAs, such as finerenone, and how do they compare to other treatments?